Treatment Decision-Making in a Patient With Advanced NSCLC CME

Author Information and Disclosures

Community CME activities are developed in part from discussions by physicians in Medscape Physician Connect.

Release Date: September 23, 2008; Valid for credit through September 23, 2009

Credits Available
Physicians - maximum of 0.25 AMA PRA Category 1 Credit(s)™ for physicians

To participate in this internet activity: (1) review the target audience, learning objectives, and author disclosures; (2) study the education content; (3) take the post-test and/or complete the evaluation; (4) view/print certificate View details.

Legal Disclaimer

The material presented here does not necessarily reflect the views of Medscape or companies that support educational programming on www.medscape.com. These materials may discuss therapeutic products that have not been approved by the US Food and Drug Administration and off-label uses of approved products. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.

Copyright © 2008 Medscape.
Medscape
Learning Objectives
Upon completion of this activity, participants will be able to:
  1. Identify aspects of the work-up of patients with advanced non-small-cell lung cancer (NSCLC) that have recently become relevant in clinical decision-making based on novel targeted therapy treatment options
  2. Cite new data that demonstrate a survival benefit from incorporating targeted therapy in combination with platinum-based doublet chemotherapy in patients with NSCLC
  3. Discuss the demonstrated clinical benefit of administering second-line therapy immediately after first-line chemotherapy vs when there is clear evidence of disease progression in patients with NSCLC
Authors and Disclosures

Howard (Jack) West, MD
Disclosure: Howard (Jack) West, MD, has disclosed that he has received grants for educational activities from Eli Lilly. Dr. West has also disclosed that he has served as an advisor or consultant to Eli Lilly and AstraZeneca.


Margie Miller
Disclosure: Margie Miller has disclosed no relevant financial relationships.


Jill W. Chamberlain
Disclosure: Jill W. Chamberlain has disclosed no relevant financial relationships.
 
Medscape
Medscape, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Medscape, LLC designates this educational activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Contact This Provider

All material on this website is protected by copyright, Copyright © 1994-2008 by Medscape. This website also contains material copyrighted by 3rd parties.